Project Grant R41EB034141
Award Date 2/15/23
Completion Date 1/31/25
Dollars Obligated $300K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
- This Project Grant from the National Institutes of Health National Cancer Institute totaling $1,170,174 was awarded to Trevarx Biomedical, Inc. on April 1, 2021 with a completion date of March 31, 2022. The grant supports development of an optimized synthesis platform for the radiotracer [18F]FTT under the Cancer Treatment Research program (CFDA 93.395). Specifically, the funding will allow Trevarx Biomedical and the University of Pennsylvania to determine the best method for synthesizing...
- This $633,218 project grant awarded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) aims to develop innovative methods for introducing radiolabeled trifluoromethyl groups into molecules for use as positron emission tomography (PET) tracers. The key objectives are to: Develop a general strategy to transform alkyl halides into their corresponding...
- This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), supports the development of radiofluorination methods and prosthetic groups for rapid construction of PET tracer analogs. The $122,260 award to the University of North Carolina at Chapel Hill will fund research to promote the utilization of quick candidate screening strategies...
- This federal Project Grant award from the National Center for Advancing Translational Sciences (NCATS) under CFDA 93.350 provides $406,500.00 to Syntr Health Technologies, Inc. to develop an automated, microfluidic tissue dissociation platform called the SYNTRFUGE. This device aims to rapidly and efficiently process solid tumor tissue samples into single cells for diagnostic analysis and research, addressing a critical barrier to more widespread use of single-cell analysis in oncology. The...
- The National Science Foundation awarded Theracea Pharma LC a $256,000 Project Grant under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop bioconjugation and preparation of fluorine-18 biomolecules for positron emission tomography (PET) imaging. The grant period runs from August 15, 2021 through July 31, 2023 in Tucson, Arizona. Under this award, Theracea Pharma LC will work to advance science and engineering research and innovation leading to breakthrough...
- This Project Grant award of $1,640,169 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) supports Synvivia, Inc.'s development of a platform to identify cyclic peptides that can increase the yield and quality of adeno-associated virus (AAV) vectors for gene therapy manufacturing. The key products and services to be delivered include: Demonstrating that Synvivia's cyclic peptide discovery library contains compounds that...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $799,962 to Tripill Biotechnology, Corp. to develop radiolabeled PSMA agents with low salivary gland uptake for improved prostate cancer imaging and therapy. The key products and services to be delivered include: Constructing PSMA derivative compounds, such as NOTA-UNC-PSMA2, that can selectively reduce salivary gland uptake while maintaining high tumor uptake in prostate...
- This $384,863 Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" (CFDA 93.286) program supports research to develop a novel radiotracer imaging agent for detecting Gram-positive bacterial infections associated with implanted medical devices. The key products and services to be delivered include: In vitro testing of a bivalent radiotracer agent...
- This Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), aims to establish proof-of-concept for applying targeted fluorination to enhance the pharmacological properties of recombinant protein therapeutics (RPTs) for the treatment of inborn errors of metabolism. The $306,873 award to Halide Biologics, Inc. will fund the development of novel RPT variants with...
- This Project Grant award from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Targeting Systems to develop a novel intramuscular gene delivery platform capable of sustained expression and endogenous secretion of bispecific natural killer cell engager (BIKE) therapeutics to treat solid tumors like hepatocellular carcinoma. The platform aims to deliver BIKEs in a less invasive manner than current immunotherapies,...